

**Pharmaceutical-Grade Sodium Chloride Market by Grade (API-NaCl, HD-NaCl), Application (Injectables /Intravenous Solutions, Dialysis, Oral Rehydration Salts, Hemofiltration Solutions, Mechanical Cleansing Solutions), and Region - Global Forecast to 2030**

Market Report | 2025-12-02 | 253 pages | MarketsandMarkets

**AVAILABLE LICENSES:**

- Single User \$4950.00
- Multi User \$6650.00
- Corporate License \$8150.00
- Enterprise Site License \$10000.00

**Report description:**

The pharmaceutical-grade sodium chloride market size is estimated to be USD 0.59 billion in 2025 and is projected to reach USD 0.77 billion by 2030, at a CAGR of 5.6% from 2025 to 2030. The pharmaceutical-grade sodium chloride market will expand owing to the rise in the demand for intravenous fluids, the injectable formulations, and dialysis solutions as the prevalence of chronic diseases like chronic kidney disease (CKD), diabetes, and dehydration disorders continues to rise. The increased production of pharmaceuticals and biologics, including in the emerging economies, is also contributing to the demand for high-purity sodium chloride that is pharmacopeially acceptable. Investment in infrastructure facilities, government expenditure on critical care, and enhancements to supply chain facilities are also driving the market's growth.

<https://mnmimg.marketsandmarkets.com/Images/pharmaceutical-grade-sodium-chloride-market-img-overview.webp>

"HD-NaCl segment is projected to exhibit the highest CAGR from 2025 to 2030"

The HD-NaCl is expected to record the highest CAGR in the pharmaceutical-grade sodium chloride market during the forecast period, owing to the rising demand for critical care therapies and hydration therapies provided in hospitals. Consumption of HD sodium chloride is on the rise. It is cheaper and can be produced in large quantities, making it the preferred choice over API sodium chloride for large-scale pharmaceutical and clinical usage.

"Dialysis segment is projected to capture the largest market share in 2030"

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

The largest application in the pharmaceutical-grade sodium chloride market is dialysis due to the rapidly rising incidences of CKD associated with older people, diabetes, and hypertension. The growth of dialysis facilities and the introduction of home dialysis units worldwide only escalates the market demand. The dialytic modalities of hemodialysis and peritoneal dialysis necessitate constant and high-volume utilization of pharmaceutical-grade sodium chloride to formulate the dialysates.

"Asia Pacific pharmaceutical-grade sodium chloride market is projected to grow at the highest CAGR during the forecast period" The Asia Pacific is experiencing high growth in the pharmaceutical-grade sodium chloride market due to the rapid development of the pharmaceutical and biologics production industry, as well as increased investment in hospital and dialysis infrastructure. Favorable government policies and low cost of production deter competitive imported pharmaceutical-grade sodium chloride production. The increased use of modern healthcare in India, China, and Southeast Asia is reinforcing market acceleration.

By Company Type: Tier 1 - 25%, Tier 2 - 42%, and Tier 3 - 33%

By Designation: C-level Executives - 20%, Directors - 30%, and Others - 50%

By Region: North America - 20%, Europe - 10%, Asia Pacific - 40%, South America - 10%, and Middle East & Africa - 20%

Notes: Other designations include sales, marketing, and product managers.

Tier 1: >USD 1 Billion; Tier 2: USD 500 million-1 Billion; and Tier 3: <USD 500 million

Companies Covered: K+S Aktiengesellschaft (Germany), Sudwestdeutsche Salzwerke AG (Germany), Dominion Salt (New Zealand), Morton Salt, Inc. (US), and Salinen Austria AG (Austria), among other companies, are covered in the report.

The study includes an in-depth competitive analysis of these key players in the pharmaceutical-grade sodium chloride market, with their company profiles, recent developments, and key market strategies.

#### Research Coverage

This research report categorizes the pharmaceutical-grade sodium chloride market based on grade (API-NaCl and HD-NaCl), application (injectables/intravenous solutions, dialysis, oral rehydration salts, hemofiltration solutions, mechanical cleansing solutions, and other applications), and region (Asia Pacific, North America, Europe, South America, and the Middle East & Africa). The report's scope covers detailed information regarding the drivers, restraints, challenges, and opportunities influencing the growth of the market. A detailed analysis of the key industry players has been done to provide insights into their business overview, products offered, and key strategies, such as partnerships, expansions, and acquisitions, associated with the market. This report also covers a competitive analysis of upcoming startups in the pharmaceutical-grade sodium chloride market ecosystem.

#### Reasons to Buy the Report

The report will provide market leaders/new entrants with information on the closest approximations of the revenue numbers for the overall pharmaceutical-grade sodium chloride market and its subsegments. This report will help stakeholders understand the competitive landscape, gain deeper insights into positioning their businesses more effectively, and develop suitable go-to-market strategies. The report will help stakeholders understand the market and provide them with information on key market drivers, restraints, challenges, and opportunities.

The report provides insights into the following points:

Analysis of key drivers (Rising dialysis treatments), restraints (Complex regulatory approvals), opportunities (Rising healthcare investment in developing regions), and challenges (Audits and documentation burdens)

- Product Development/Innovation: Detailed insights into upcoming technologies, research & development activities, and product & service launches in the pharmaceutical-grade sodium chloride market

- Market Development: Comprehensive information about profitable markets-the report analyzes the pharmaceutical-grade sodium chloride market across varied regions

- Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the pharmaceutical-grade sodium chloride market

- Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players, such as K+S Aktiengesellschaft (Germany), Sudwestdeutsche Salzwerke AG (Germany), Dominion Salt (New Zealand), Morton Salt, Inc. (US), Salinen Austria AG (Austria)

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

## Table of Contents:

1	INTRODUCTION	25
1.1	STUDY OBJECTIVES	25
1.2	MARKET DEFINITION	25
1.3	STUDY SCOPE	26
1.3.1	MARKETS COVERED AND REGIONAL SCOPE	26
1.3.2	INCLUSIONS AND EXCLUSIONS	26
1.3.3	YEARS CONSIDERED	27
1.3.4	CURRENCY CONSIDERED	27
1.3.5	UNIT CONSIDERED	27
1.4	STAKEHOLDERS	28
1.5	SUMMARY OF STRATEGIC CHANGES	28
2	EXECUTIVE SUMMARY	29
2.1	KEY INSIGHTS AND MARKET HIGHLIGHTS	29
2.2	KEY MARKET PARTICIPANTS: SHARE INSIGHTS AND STRATEGIC DEVELOPMENTS	30
2.3	DISRUPTIVE TRENDS SHAPING PHARMACEUTICAL-GRADE SODIUM CHLORIDE MARKET	31
2.4	HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS	32
2.5	SNAPSHOT: ASIA PACIFIC MARKET SIZE AND FORECAST	33
3	PREMIUM INSIGHTS	34
3.1	ATTRACTIVE OPPORTUNITIES FOR PLAYERS IN PHARMACEUTICAL-GRADE SODIUM CHLORIDE MARKET	34
3.2	PHARMACEUTICAL-GRADE SODIUM CHLORIDE MARKET, BY GRADE AND REGION	35
3.3	PHARMACEUTICAL-GRADE SODIUM CHLORIDE MARKET, BY PRODUCT FORM	35
3.4	PHARMACEUTICAL-GRADE SODIUM CHLORIDE MARKET, BY APPLICATION	36
3.5	PHARMACEUTICAL-GRADE SODIUM CHLORIDE MARKET, BY COUNTRY	36
4	MARKET OVERVIEW	37
4.1	INTRODUCTION	37
4.2	MARKET DYNAMICS	38
4.2.1	DRIVERS	38
4.2.1.1	Rising dialysis treatments	38
4.2.1.2	Strong demand for pharmaceutical-grade sodium chloride in North America and Europe	40
4.2.1.3	Emerging markets driving healthcare expansion and increasing demand	41
4.2.2	RESTRAINTS	41
4.2.2.1	Complex regulatory approvals	41
4.2.2.2	Dependence on stable supply of raw salt	42
?		
4.2.3	OPPORTUNITIES	42
4.2.3.1	Rising healthcare investment in developing regions	42
4.2.3.2	Partnerships with hospitals and pharmaceutical companies	43
4.2.4	CHALLENGES	43
4.2.4.1	Strict audits and documentation burdens	43
4.2.4.2	Competition from local low-cost producers	44
4.3	UNMET NEEDS AND WHITE SPACES	44
4.3.1	UNMET NEEDS IN PHARMACEUTICAL-GRADE SODIUM CHLORIDE MARKET	44
4.3.1.1	Need for higher purity and specialized grades	44
4.3.1.2	Digitalization and supply chain transparency	45
4.3.1.3	Enhanced technical support and quality services	45
4.3.1.4	Flexible and long-term supply models	45

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

4.3.1.5	Skilled quality teams and regulatory assurance	45
4.3.2	WHITE SPACE OPPORTUNITIES	45
4.3.2.1	Expansion into emerging and underserved markets	45
4.3.2.2	Development of specialty and high-performance grades	46
4.3.2.3	Digital quality systems and traceability platforms	46
4.3.2.4	Enhanced technical services and regulatory support	46
4.3.2.5	Integrated supply and capacity-reliability solutions	46
4.4	INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES	47
4.4.1	INTERCONNECTED MARKETS	47
4.4.2	CROSS-SECTOR OPPORTUNITIES	47
4.5	STRATEGIC MOVES BY TIER 1/2/3 PLAYERS	48
4.5.1	KEY MOVES AND STRATEGIC FOCUS	48
5	INDUSTRY TRENDS	49
5.1	PORTER'S FIVE FORCES' ANALYSIS	49
5.1.1	THREAT OF NEW ENTRANTS	50
5.1.2	THREAT OF SUBSTITUTES	50
5.1.3	BARGAINING POWER OF SUPPLIERS	50
5.1.4	BARGAINING POWER OF BUYERS	51
5.1.5	INTENSITY OF COMPETITIVE RIVALRY	51
5.2	MACROECONOMIC ANALYSIS	52
5.2.1	INTRODUCTION	52
5.2.2	GDP TRENDS AND FORECASTS	52
5.2.3	URBANIZATION AND DEMOGRAPHIC SHIFTS	53
5.2.4	TRADE AND GLOBAL SUPPLY CHAIN DYNAMICS	54
5.3	VALUE CHAIN ANALYSIS	55
5.3.1	RAW MATERIAL PROCUREMENT AND ACQUISITION	56
5.3.2	PROCESSING, REFINING, AND QUALITY ASSURANCE	56
5.3.3	DISTRIBUTION, LOGISTICS, AND SUPPLY CHAIN MANAGEMENT	57
5.3.4	CONVERSION TO END-USE PHARMACEUTICAL PRODUCTS	57
5.4	ECOSYSTEM ANALYSIS	57
5.5	PRICING ANALYSIS	58
5.5.1	AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY GRADE	59
5.5.2	AVERAGE SELLING PRICE TREND, BY REGION	59
5.6	TRADE ANALYSIS	60
5.6.1	IMPORT SCENARIO	61
5.6.2	EXPORT SCENARIO	62
5.7	KEY CONFERENCES AND EVENTS, 2025-2026	64
5.8	TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS	64
5.9	CASE STUDY ANALYSIS	65
5.9.1	EFFICIENT PRODUCTION OF PHARMACEUTICAL-GRADE SODIUM CHLORIDE FROM ROCK SALT AT ENASEL, ALGERIA	65
5.9.2	TRANSFORMING LOW-QUALITY SOLAR SALT INTO PHARMACEUTICAL-GRADE SODIUM CHLORIDE IN BANGLADESH	66
5.10	IMPACT OF 2025 US TARIFF ON PHARMACEUTICAL-GRADE SODIUM CHLORIDE MARKET	66
5.10.1	INTRODUCTION	66
5.10.2	KEY TARIFF RATES	67
5.10.3	PRICE IMPACT ANALYSIS	67
5.10.4	KEY IMPACT ON VARIOUS REGIONS	68
5.10.5	IMPACT ON APPLICATIONS	68

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

6	STRATEGIC DISRUPTION THROUGH TECHNOLOGY, PATENTS, DIGITAL, AND AI ADOPTIONS	69
6.1	KEY TECHNOLOGIES	69
6.1.1	VACUUM SALT PRODUCTION	69
6.1.2	MECHANICAL VAPOR RECOMPRESSION (MVR) & MULTIPLE-EFFECT EVAPORATION (MEE)	69
6.1.3	RECRYSTALLIZATION	69
6.1.4	COLD BRINE LEACHING & CHEMICAL PRECIPITATION	69
6.2	COMPLEMENTARY TECHNOLOGIES	69
6.2.1	PARTICLE SIZE CONTROL, SIEVING, AND GRANULATION	70
6.2.2	DRYING TECHNOLOGY (HOT AIR & FLUID BED DRYING)	70
6.2.3	PAT & PROCESS AUTOMATION (SCADA, DCS, INLINE QUALITY MONITORING)	70
6.3	ADJACENT TECHNOLOGIES	70
6.3.1	STERILE INTRAVENOUS FLUID, DIALYSIS, AND ORS PRODUCTION SYSTEMS	70
6.3.2	CLEANROOM, HVAC, AND GMP PACKAGING TECHNOLOGIES	70
6.4	TECHNOLOGY/PRODUCT ROADMAP	70
6.4.1	SHORT-TERM (2025-2027)   DIGITAL TRANSITION AND PRODUCTION OPTIMIZATION PHASE	70
6.4.2	MID-TERM (2027-2030): SUSTAINABLE PRODUCTION & SUPPLY CHAIN INTEGRATION	71
6.4.3	LONG-TERM (2030-2035+): BIOPROCESS INTEGRATION & ON-SITE PHARMACEUTICAL BRINE SYSTEMS	72
6.5	PATENT ANALYSIS	72
6.5.1	INTRODUCTION	72
6.5.2	APPROACH	73
6.5.3	TOP APPLICANTS	73
6.6	FUTURE APPLICATIONS	75
6.6.1	ADVANCED APPLICATIONS IN INJECTABLES, DIALYSIS, AND BIOPROCESSING SYSTEMS	75
6.7	IMPACT OF AI/GEN AI ON PHARMACEUTICAL-GRADE SODIUM CHLORIDE MARKET	76
6.7.1	TOP USE CASES AND MARKET POTENTIAL	76
6.7.2	INTERCONNECTED ADJACENT ECOSYSTEM AND IMPACT ON MARKET PLAYERS	77
6.7.3	CLIENTS' READINESS TO ADOPT GENERATIVE AI IN PHARMACEUTICAL-GRADE SODIUM CHLORIDE MARKET	77
6.8	SUCCESS STORIES AND REAL-WORLD APPLICATIONS	78
6.8.1	K+S AKTIENGESELLSCHAFT ENABLES CRITICAL PHARMACEUTICAL SUPPLY SUPPORT DURING GLOBAL COVID-19 VACCINATION ROLLOUT	78
7	SUSTAINABILITY AND REGULATORY LANDSCAPE	79
7.1	REGIONAL REGULATIONS AND COMPLIANCE	79
7.1.1	REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	79
7.1.2	INDUSTRY STANDARDS	82
7.2	SUSTAINABILITY INITIATIVES	83
7.2.1	CARBON IMPACT AND ECO-APPLICATIONS OF PHARMACEUTICAL-GRADE SODIUM CHLORIDE	83
7.2.1.1	Carbon Impact Reduction	84
7.2.1.2	Eco-Applications	84
7.3	CERTIFICATIONS, LABELING, ECO-STANDARDS	85
8	CUSTOMER LANDSCAPE & BUYER BEHAVIOR	87
8.1	DECISION-MAKING PROCESS	87
8.2	BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA	89
8.2.1	KEY STAKEHOLDERS IN BUYING PROCESS	89
8.2.2	BUYING CRITERIA	90
8.3	ADOPTION BARRIERS & INTERNAL CHALLENGES	91
8.4	UNMET NEEDS FROM VARIOUS APPLICATIONS	93

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 8.5 MARKET PROFITABILITY 93
  - 8.5.1 REVENUE POTENTIAL 93
  - 8.5.2 COST DYNAMICS 94
  - 8.5.3 MARGIN OPPORTUNITIES, BY APPLICATION 94
- 9 PHARMACEUTICAL-GRADE SODIUM CHLORIDE MARKET, BY GRADE 95
  - 9.1 INTRODUCTION 96
  - 9.2 HD-NACL 97
    - 9.2.1 UNMATCHED STABILITY, HEIGHT, AND LIFTING POWER TO DRIVE DEMAND 97
  - 9.3 API-NACL 97
    - 9.3.1 HIGH REGULATORY COMPLIANCE, PURITY ASSURANCE, AND FUNCTIONAL PERFORMANCE TO AUGMENT DEMAND 97
- 10 PHARMACEUTICAL-GRADE SODIUM CHLORIDE MARKET, BY PRODUCT FORM 99
  - 10.1 INTRODUCTION 100
  - 10.2 LIQUID 101
    - 10.2.1 GROWING DEMAND FOR ORAL ELECTROLYTE THERAPIES TO DRIVE DEMAND 101
  - 10.3 SOLID 101
    - 10.3.1 RISING GLOBAL HOSPITALIZATION RATES TO AUGMENT DEMAND 101
- 11 PHARMACEUTICAL-GRADE SODIUM CHLORIDE MARKET, BY APPLICATION 102
  - 11.1 INTRODUCTION 103
  - 11.2 DIALYSIS 104
    - 11.2.1 GROWING DIALYSIS PATIENT POPULATION TO FUEL MARKET GROWTH 104
  - 11.3 INJECTABLES 105
    - 11.3.1 GROWING USE OF IV THERAPIES AND SURGICAL PROCEDURES TO DRIVE DEMAND 105
  - 11.4 ORAL REHYDRATION SALTS 105
    - 11.4.1 GROWING GLOBAL NEED FOR EFFECTIVE DEHYDRATION MANAGEMENT TO DRIVE DEMAND 105
  - 11.5 HEMOFILTRATION SOLUTIONS 106
    - 11.5.1 ADVANCED RENAL REPLACEMENT REQUIREMENTS TO ACCELERATE DEMAND 106
  - 11.6 MECHANICAL CLEANING SOLUTIONS 107
    - 11.6.1 INCREASING SURGICAL ACTIVITIES AND HOSPITAL HYGIENE STANDARDS TO DRIVE DEMAND 107
  - 11.7 OTHER APPLICATIONS 107
- 12 PHARMACEUTICAL-GRADE SODIUM CHLORIDE MARKET, BY REGION 109
  - 12.1 INTRODUCTION 110
  - 12.2 ASIA PACIFIC 111
    - 12.2.1 CHINA 115
      - 12.2.1.1 Pharmaceutical industry and shift toward advanced drug development to drive market 115
    - 12.2.2 JAPAN 116
      - 12.2.2.1 Accelerating aging population and rising healthcare demand to drive market 116
    - 12.2.3 INDIA 118
      - 12.2.3.1 Growing generic injectable drug industry to drive market 118
  - 12.2.4 SOUTH KOREA 120
    - 12.2.4.1 Rapidly aging population and rising healthcare demand to propel market 120
  - 12.2.5 REST OF ASIA PACIFIC 122
- 12.3 EUROPE 124
  - 12.3.1 GERMANY 128
    - 12.3.1.1 Rising renal replacement therapy demand to boost consumption 128
  - 12.3.2 FRANCE 130

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 12.3.2.1 Growing adoption of home hemodialysis 130
- 12.3.3 UK 132
  - 12.3.3.1 CKD prevalence and aging population to accelerate market 132
  - 12.3.4 ITALY 134
    - 12.3.4.1 Expanding healthcare infrastructure to drive demand 134
    - 12.3.5 SPAIN 136
      - 12.3.5.1 Strong organ donation infrastructure and rising dialysis volume to accelerate market growth 136
    - 12.3.6 NETHERLANDS 138
      - 12.3.6.1 Increasing CKD incidence and elderly population expansion to support market growth 138
    - 12.3.7 IRELAND 140
      - 12.3.7.1 Increasing incidence of kidney failure and expanding renal care needs to boost market 140
    - 12.3.8 TURKEY 142
      - 12.3.8.1 High incidence of end-stage kidney disease to boost market 142
    - 12.3.9 RUSSIA 143
      - 12.3.9.1 Expanding dialysis centers and rising CKD burden to propel market 143
    - 12.3.10 REST OF EUROPE 145
  - 12.4 NORTH AMERICA 147
    - 12.4.1 US 150
      - 12.4.1.1 Aging population increasing hospital and infusion needs to boost market 150
    - 12.4.2 CANADA 152
      - 12.4.2.1 Rising CKD and expanding dialysis needs to boost market 152
    - 12.4.3 MEXICO 154
      - 12.4.3.1 Rapidly aging population to propel the market 154
  - 12.5 SOUTH AMERICA 155
    - 12.5.1 BRAZIL 158
      - 12.5.1.1 Rising CKD burden and rapid population aging fueling the demand 158
    - 12.5.2 ARGENTINA 160
      - 12.5.2.1 Healthcare modernization and rising chronic disease burden to augment market 160
    - 12.5.3 REST OF SOUTH AMERICA 161
  - ?
  - 12.6 MIDDLE EAST & AFRICA 163
    - 12.6.1 GCC COUNTRIES 165
      - 12.6.1.1 Saudi Arabia 167
        - 12.6.1.1.1 High CKD and diabetes burden paired with Vision 2030 healthcare expansion to drive market 167
        - 12.6.1.2 UAE 169
          - 12.6.1.2.1 High diabetes and CKD burden to boost market 169
      - 12.6.1.3 Rest of GCC countries 170
    - 12.6.2 SOUTH AFRICA 172
      - 12.6.2.1 Expanding healthcare & dialysis infrastructure to drive market 172
    - 12.6.3 REST OF MIDDLE EAST & AFRICA 174
  - 13 COMPETITIVE LANDSCAPE 176
    - 13.1 OVERVIEW 176
    - 13.2 KEY PLAYER STRATEGIES 176
    - 13.3 REVENUE ANALYSIS 177
    - 13.4 MARKET SHARE ANALYSIS 177
    - 13.5 COMPANY VALUATION AND FINANCIAL METRICS 180
      - 13.5.1 COMPANY VALUATION 180

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

13.5.2	FINANCIAL METRICS	181
13.6	BRAND/PRODUCT COMPARISON	183
13.7	COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024	184
13.7.1	STARS	184
13.7.2	EMERGING LEADERS	184
13.7.3	PERVASIVE PLAYERS	184
13.7.4	PARTICIPANTS	184
13.7.5	COMPANY FOOTPRINT: KEY PLAYERS, 2024	186
13.7.5.1	Company footprint	186
13.7.5.2	Region footprint	187
13.7.5.3	Grade footprint	187
13.7.5.4	Product form footprint	188
13.7.5.5	Application footprint	188
13.8	COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024	189
13.8.1	PROGRESSIVE COMPANIES	189
13.8.2	RESPONSIVE COMPANIES	189
13.8.3	DYNAMIC COMPANIES	189
13.8.4	STARTING BLOCKS	189
13.8.5	COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024	191
13.8.6	DETAILED LIST OF KEY STARTUPS/SMES	191
13.8.7	COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES	192
	?	
13.9	COMPETITIVE SCENARIO	193
13.9.1	DEALS	193
13.9.2	EXPANSIONS	194
13.9.3	OTHER DEVELOPMENTS	194
14	COMPANY PROFILES	195
14.1	KEY PLAYERS	195
14.1.1	K+S AKTIENGESELLSCHAFT	195
14.1.1.1	Business overview	195
14.1.1.2	Products/Solutions/Services offered	196
14.1.1.3	Recent developments	197
14.1.1.3.1	Others	197
14.1.1.4	MnM view	197
14.1.1.4.1	Key strengths	197
14.1.1.4.2	Strategic choices	198
14.1.1.4.3	Weaknesses and competitive threats	198
14.1.2	SUDWESTDEUTSCHE SALZWERKE AG	199
14.1.2.1	Business overview	199
14.1.2.2	Products/Solutions/Services offered	200
14.1.2.3	MnM view	201
14.1.2.3.1	Key strengths	201
14.1.2.3.2	Strategic choices	201
14.1.2.3.3	Weaknesses and competitive threats	202
14.1.3	DOMINION SALT	203
14.1.3.1	Business overview	203
14.1.3.2	Products/Solutions/Services offered	203

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

14.1.3.3	MnM view	204
14.1.3.3.1	Key strengths	204
14.1.3.3.2	Strategic choices	204
14.1.3.3.3	Weaknesses and competitive threats	204
14.1.4	MORTON SALT, INC.	205
14.1.4.1	Business overview	205
14.1.4.2	Products/Solutions/Services offered	205
14.1.4.3	MnM view	206
14.1.4.3.1	Key strengths	206
14.1.4.3.2	Strategic choices	206
14.1.4.3.3	Weaknesses and competitive threats	206
14.1.5	SALINEN AUSTRIA AG	207
14.1.5.1	Business overview	207
14.1.5.2	Products/Solutions/Services offered	207
14.1.5.3	MnM view	208
14.1.5.3.1	Key strengths	208
14.1.5.3.2	Strategic choices	208
14.1.5.3.3	Weaknesses and competitive threats	208
14.1.6	MERCK KGAA	209
14.1.6.1	Business overview	209
14.1.6.2	Products/Solutions/Services offered	211
14.1.6.3	Recent developments	211
14.1.6.3.1	Expansions	211
14.1.6.4	MnM view	212
14.1.7	GROUPE SALINS	213
14.1.7.1	Business overview	213
14.1.7.2	Products/Solutions/Services offered	214
14.1.7.3	Recent developments	214
14.1.7.3.1	Deals	214
14.1.7.4	MnM view	215
14.1.8	HUB SALT	216
14.1.8.1	Business overview	216
14.1.8.2	Products/Solutions/Services offered	216
14.1.8.3	MnM view	217
14.1.9	JIANGSU PROVINCE QINFEN PHARMACEUTICAL CO., LTD.	218
14.1.9.1	Business overview	218
14.1.9.2	Products/Solutions/Services offered	218
14.1.9.3	MnM view	219
14.1.10	US SALT	220
14.1.10.1	Business overview	220
14.1.10.2	Products/Solutions/Services offered	220
14.1.10.3	MnM view	220
14.2	OTHER PLAYERS	221
14.2.1	NANDU CHEMICALS	221
14.2.2	MACCO ORGANIQUES, S.R.O.	222
14.2.3	J J CHEMICALS	223
14.2.4	SALT MINERALS GMBH	224

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

14.2.5	HITECH MINERALS AND CHEMICALS GROUP	225
14.2.6	TIANJIN HENGHAIXIN INTERNATIONAL TRADING CO., LTD.	226
14.2.7	MARKHOR SALT CO.	227
14.2.8	ABHAY AQUA CHEM	228
14.2.9	HAWKINS	229
14.2.10	RCI LABSCAN LIMITED	230
14.2.11	GLENTHAM LIFE SCIENCES LIMITED	231
14.2.12	FENGCHEN GROUP CO., LTD	232
14.2.13	DHANRAJ SUGAR PVT. LTD.	233
14.2.14	SD FINE-CHEM LTD	234
14.2.15	VM CHEMICALS	235
15	RESEARCH METHODOLOGY	236
15.1	RESEARCH DATA	236
15.1.1	SECONDARY DATA	236
15.1.1.1	Key data from secondary sources	237
15.1.2	PRIMARY DATA	237
15.1.2.1	Key data from primary sources	238
15.1.2.2	Key industry insights	238
15.2	MARKET SIZE ESTIMATION	239
15.3	BASE NUMBER CALCULATION	240
15.3.1	DEMAND-SIDE APPROACH	240
15.3.2	SUPPLY-SIDE APPROACH	241
15.4	MARKET FORECAST APPROACH	241
15.4.1	SUPPLY SIDE	241
15.4.2	DEMAND SIDE	241
15.5	DATA TRIANGULATION	241
15.6	FACTOR ANALYSIS	242
15.7	RESEARCH ASSUMPTIONS	243
15.8	RESEARCH LIMITATIONS AND RISK ASSESSMENT	244
16	APPENDIX	245
16.1	DISCUSSION GUIDE	245
16.2	KNOWLEDGESTORE: MARKETSDMARKETS' SUBSCRIPTION PORTAL	249
16.3	CUSTOMIZATION OPTIONS	251
16.4	RELATED REPORTS	251
16.5	AUTHOR DETAILS	252

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

**Pharmaceutical-Grade Sodium Chloride Market by Grade (API-NaCl, HD-NaCl),  
Application (Injectables /Intravenous Solutions, Dialysis, Oral Rehydration Salts,  
Hemofiltration Solutions, Mechanical Cleansing Solutions), and Region - Global  
Forecast to 2030**

Market Report | 2025-12-02 | 253 pages | MarketsandMarkets

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

**ORDER FORM:**

Select license	License	Price
	Single User	\$4950.00
	Multi User	\$6650.00
	Corporate License	\$8150.00
	Enterprise Site License	\$10000.00
		VAT
		Total

\*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Zip Code\*

Country\*

Date

2026-03-02

Signature

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

[www.scotts-international.com](http://www.scotts-international.com)